Payment overview · 2025
General Payments
$916.56
56 reported records · 15 companies
Healthcare provider profile · identity verified
Emma Rubin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SCRANTON, PA · NPI 1902965924
Verified facts
What the public records show
CMS Open Payments records show Emma Rubin, M.D. received $916.56 in general payments during 2025 across 56 reported records.
Lilly USA, LLC accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $198.33 | 21.6% | 18 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $167.09 | 18.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.52 | 11.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.33 | 8.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.91 | 7.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.30 | 6.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.18 | 5.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.68 | 4.2% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $37.54 | 4.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $28.23 | 3.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.18 | 2.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.20 | 2.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.83 | 1.8% | 1 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $14.64 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.60 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $916.56 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $167.09 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $132.81 | 13 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $69.91 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.02 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.88 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.40 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.33 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $28.23 | 2 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 361 | 73 |
| Alprazolam | Alprazolam | 283 | 41 |
| Lisinopril | Lisinopril | 275 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 70 |
| Omeprazole | Omeprazole | 236 | 62 |
| Metformin Hcl | Metformin Hcl | 231 | 63 |
| Losartan Potassium | Losartan Potassium | 216 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 201 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 48 |
| Gabapentin | Gabapentin | 188 | 42 |
| Simvastatin | Simvastatin | 188 | 45 |
| Eliquis | Apixaban | 176 | 27 |
| Lorazepam | Lorazepam | 155 | 29 |
| Furosemide | Furosemide | 152 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 34 |
| Tramadol Hcl | Tramadol Hcl | 141 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 25 |
| Azithromycin | Azithromycin | 101 | 70 |
| Metformin Hcl Er | Metformin Hcl | 101 | 24 |
| Famotidine | Famotidine | 96 | 26 |
| Potassium Chloride | Potassium Chloride | 93 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 19 |
| Jardiance | Empagliflozin | 80 | 17 |
| Farxiga | Dapagliflozin Propanediol | 79 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 17 |
| Ozempic | Semaglutide | 78 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 15 |
| Methylprednisolone | Methylprednisolone | 69 | 41 |
| Diazepam | Diazepam | 67 | 11 |
| Allopurinol | Allopurinol | 63 | 19 |
| Sertraline Hcl | Sertraline Hcl | 62 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 21 |
| Tradjenta | Linagliptin | 60 | 11 |
| Irbesartan | Irbesartan | 56 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 15 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 31 |
| Synthroid | Levothyroxine Sodium | 44 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 30 |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 31 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Felodipine Er | Felodipine | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $916.56 · 56 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, CONTRAVE, CREON, Cologuard Collection Kit, ENTYVIO, FARXIGA, GARDASIL 9, JARDIANCE, LINZESS, MOUNJARO, OMVOH, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, Sucraid, TREMFYA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VAXNEUVANCE, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error